We demonstrated a low NKILA expression in laryngeal cancer and its correlation with shorter overall survival in patients with laryngeal cancer. NKILA serves as a tumor suppressor in laryngeal cancer by suppressing laryngeal cancer cell viability and migration, whereas promoting cell apoptosis; NKILA knockdown reverses the cytotoxicity of X-ray radiation on laryngeal cancer cells through combining with NF-kB: IkB complex to inhibit IkB phosphorylation, inhibit p65 nuclear translocation, and finally inhibit NF-kB activation. NF-kB binds to the promoter region of NKILA to activate its transcriptional activity, upregulated NKILA then inhibits IkB phosphorylation and NF-kB activation, thus forming a negative feedback loop to sensitize laryngeal cancer cell to X-ray radiation.